ProShare Advisors
CRVS icon

ProShare Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

ProShare Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$191K Sell
13,025
-739
-5% -$11.8K ﹤0.01% 1604
2025
Q4 		$106K Buy
13,764
+979
+8% +$7.72K ﹤0.01% 1863
2025
Q3 		$94.2K Sell
12,785
-835
-6% -$4.27K ﹤0.01% 1854
2025
Q2 		$54.5K Buy
+13,620
New +$49.6K ﹤0.01% 1980
2018
Q4 		– Sell
-13,604
Closed -$117K – 1604
2018
Q3 		$117K Sell
13,604
-491
-3% -$4.91K ﹤0.01% 1667
2018
Q2 		$155K Buy
14,095
+3,291
+30% +$36.7K ﹤0.01% 1664
2018
Q1 		$125K Sell
10,804
-1,783
-14% -$16.9K ﹤0.01% 1619
2017
Q4 		$130K Buy
+12,587
New +$161K ﹤0.01% 1711

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return